| - |
Cysteamine bitartrate delayed-release |
Procysbi® |
For the treatment of proven nephropathic cystinosis. |
NCPE Assessment process complete |
15th November 2017 |
 |
| - |
Daratumumab in combination with lenalidomide and dexamethasone |
Darzalex® |
For the treatment of adult patients with multiple myeloma wo have received at least one prior therapy. |
Rapid review complete |
27th November 2017 |
|
| - |
Hyaluronic acid and co enzyme Q10 |
VisuXL® |
For the treatment of dry eye disease and the treatment of post-surgical intervention following elective surgery and trauma. |
Assessment process complete |
30th November 2017 |
|
| - |
Rivaroxaban |
Xarelto® |
Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement. |
Rapid Review Complete |
22nd November 2017 |
|
| - |
Rivaroxaban |
Xarelto® |
Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE. |
Rapid Review Complete |
22nd November 2017 |
|
| - |
Sofosbuvir/Velpatasvir/Voxilaprevir |
Vosevi® |
For the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic i.e. all genotypes (GT1, 2, 3, 4, 5 and 6). |
Rapid review complete |
15th November 2017 |
|
